Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 241

1.

Identification of prostatic acid phosphatase (PAP) specific HLA-DR1-restricted T-cell epitopes.

Johnson LE, McNeel DG.

Prostate. 2012 May 15;72(7):730-40. doi: 10.1002/pros.21477. Epub 2011 Aug 30.

PMID:
22529020
2.

Identification of HLA-DRB1*1501-restricted T-cell epitopes from human prostatic acid phosphatase.

Klyushnenkova EN, Kouiavskaia DV, Kodak JA, Vandenbark AA, Alexander RB.

Prostate. 2007 Jul 1;67(10):1019-28.

PMID:
17455230
3.

HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase.

Olson BM, Frye TP, Johnson LE, Fong L, Knutson KL, Disis ML, McNeel DG.

Cancer Immunol Immunother. 2010 Jun;59(6):943-53. doi: 10.1007/s00262-010-0820-6. Epub 2010 Feb 6.

5.

Identification of HLA-DRB1*1501-restricted T-cell epitopes from prostate-specific antigen.

Klyushnenkova EN, Link J, Oberle WT, Kodak J, Rich C, Vandenbark AA, Alexander RB.

Clin Cancer Res. 2005 Apr 15;11(8):2853-61.

6.

Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells.

Johnson LE, Frye TP, Chinnasamy N, Chinnasamy D, McNeel DG.

Cancer Immunol Immunother. 2007 Jun;56(6):885-95. Epub 2006 Nov 11.

PMID:
17102977
7.

Induction of CTL response by a minimal epitope vaccine in HLA A*0201/DR1 transgenic mice: dependence on HLA class II restricted T(H) response.

BenMohamed L, Krishnan R, Longmate J, Auge C, Low L, Primus J, Diamond DJ.

Hum Immunol. 2000 Aug;61(8):764-79.

PMID:
10980387
8.

Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.

Machlenkin A, Paz A, Bar Haim E, Goldberger O, Finkel E, Tirosh B, Volovitz I, Vadai E, Lugassy G, Cytron S, Lemonnier F, Tzehoval E, Eisenbach L.

Cancer Res. 2005 Jul 15;65(14):6435-42.

9.

Identification of T helper epitopes from prostatic acid phosphatase.

McNeel DG, Nguyen LD, Disis ML.

Cancer Res. 2001 Jul 1;61(13):5161-7.

10.

Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells.

Smith HA, McNeel DG.

J Immunother. 2011 Oct;34(8):569-80. doi: 10.1097/CJI.0b013e31822b5b1d.

11.

Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP).

Johnson LE, Frye TP, Arnot AR, Marquette C, Couture LA, Gendron-Fitzpatrick A, McNeel DG.

Vaccine. 2006 Jan 16;24(3):293-303. Epub 2005 Aug 9.

PMID:
16115700
12.

Novel prostate acid phosphatase-based peptide vaccination strategy induces antigen-specific T-cell responses and limits tumour growth in mice.

Saif JM, Vadakekolathu J, Rane SS, McDonald D, Ahmad M, Mathieu M, Pockley AG, Durrant L, Metheringham R, Rees RC, McArdle SE.

Eur J Immunol. 2014 Apr;44(4):994-1004. doi: 10.1002/eji.201343863. Epub 2014 Mar 7.

13.

Identification of MHC class II-restricted T-cell epitopes in prostate-specific membrane antigen.

Schroers R, Shen L, Rollins L, Xiao Z, Sonderstrup G, Slawin K, Huang XF, Chen SY.

Clin Cancer Res. 2003 Aug 15;9(9):3260-71.

14.

CD8+ T cells specific for the androgen receptor are common in patients with prostate cancer and are able to lyse prostate tumor cells.

Olson BM, McNeel DG.

Cancer Immunol Immunother. 2011 Jun;60(6):781-92. doi: 10.1007/s00262-011-0987-5. Epub 2011 Feb 25.

15.

Identification of naturally processed CD4 T cell epitopes from the prostate-specific antigen kallikrein 4 using peptide-based in vitro stimulation.

Hural JA, Friedman RS, McNabb A, Steen SS, Henderson RA, Kalos M.

J Immunol. 2002 Jul 1;169(1):557-65.

16.

Screening of human tumor antigens for CD4 T cell epitopes by combination of HLA-transgenic mice, recombinant adenovirus and antigen peptide libraries.

Osen W, Soltek S, Song M, Leuchs B, Steitz J, Tüting T, Eichmüller SB, Nguyen XD, Schadendorf D, Paschen A.

PLoS One. 2010 Nov 30;5(11):e14137. doi: 10.1371/journal.pone.0014137.

17.

Preventive and therapeutic vaccination with PAP-3, a novel human prostate cancer peptide, inhibits carcinoma development in HLA transgenic mice.

Machlenkin A, Azriel-Rosenfeld R, Volovitz I, Vadai E, Lev A, Paz A, Goldberger O, Reiter Y, Tzehoval E, Benhar I, Eisenbach L.

Cancer Immunol Immunother. 2007 Feb;56(2):217-26. Epub 2006 Jun 1.

PMID:
16738849
18.

A modified epitope identified for generation and monitoring of PSA-specific T cells in patients on early phases of PSA-based immunotherapeutic protocols.

Lundberg K, Roos AK, Pavlenko M, Leder C, Wehrum D, Guevara-Patiño J, Andersen RS, Pisa P.

Vaccine. 2009 Mar 4;27(10):1557-65. doi: 10.1016/j.vaccine.2009.01.011. Epub 2009 Jan 24.

PMID:
19171173
19.

Development of a DNA vaccine designed to induce cytotoxic T lymphocyte responses to multiple conserved epitopes in HIV-1.

Wilson CC, McKinney D, Anders M, MaWhinney S, Forster J, Crimi C, Southwood S, Sette A, Chesnut R, Newman MJ, Livingston BD.

J Immunol. 2003 Nov 15;171(10):5611-23.

20.

Human cytotoxic CD4+ T cells recognize HLA-DR1-restricted epitopes on vaccinia virus proteins A24R and D1R conserved among poxviruses.

Mitra-Kaushik S, Cruz J, Stern LJ, Ennis FA, Terajima M.

J Immunol. 2007 Jul 15;179(2):1303-12.

Supplemental Content

Support Center